Xcout Intel
Beacon Therapeutics competitors & alternatives
The 12 closest competitors and alternatives to Beacon Therapeutics among biotechnology companies — ranked by similarity to what Beacon Therapeutics actually does, not by market-cap band.
Subscribe to see Beacon Therapeutics’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Beacon Therapeutics
Beacon Therapeutics is a clinical-stage biotechnology company dedicated to saving and restoring sight for people living with rare and prevalent ocular diseases. The company works to deliver advanced retinal gene therapies to patients experiencing blindness.
Beacon Therapeutics at a glance
Beacon Therapeutics is a biotechnology company. It has raised at least $245M across the 2 funding rounds on record. Its most recent funding round, Series B, raised $75M in January 2026. Xcout tracks 11 named people at Beacon Therapeutics, including Lance Baldo (Chief Executive Officer).
Beacon Therapeutics leadership
- Lance BaldoChief Executive Officer
- Ryan RobinsonChief Financial Officer
- Brian MullanChief Technical Officer
- Abraham ScariaChief Scientific Officer
- Daniel ChungChief Medical Officer
- David FellowsChairman
5 more named people on record for Beacon Therapeutics, with roles, board committees and tenure — see the full roster →
Beacon Therapeutics funding rounds
At least $245M raised across the 2 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series B | $75M | 5 named | |
| Series C | $170M | 6 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Top 12 Beacon Therapeutics competitors
Ranked by semantic similarity — how close each company is to Beacon Therapeutics by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar biotechnology company
Ray Therapeutics, Inc. is a privately held optogenetic gene therapy company headquartered in Berkeley, California. The company focuses on reimagining vision through innovative genetic treatments and novel therapeutic solutions.
Similar biotechnology company
Beam Therapeutics Inc., founded in 2017 and based in Cambridge, Massachusetts, operates as a pioneering biopharmaceutical firm. Its core mission involves engineering precise genetic remedies to tackle a spectrum of severe human ailments, primarily within the United States. The company's developmental portfolio features several key candidates: BEAM-101 is being advanced to treat both sickle cell disease and beta thalassemia. BEAM-102 is specifically designed for addressing sickle cell disease. BEAM-201, an allogeneic chimeric antigen receptor T-cell therapy, is under investigation for individuals suffering from relapsed or refractory T-cell acute lymphoblastic leukemia. BEAM-301 is a liver-targeted candidate aimed at patients afflicted with Glycogen Storage Disease Type Ia. Beyond these flagship programs, Beam Therapeutics is also engaged in devising treatments for alpha-1 antitrypsin deficiency, various ocular conditions, and other disorders impacting the liver, muscular system, and central nervous system. To further its research and development objectives, Beam Therapeutics has forged numerous strategic alliances and partnerships. These include collaborations with Boston Children's Hospital; a research and clinical trial agreement with Magenta Therapeutics, Inc.; a licensing deal with Sana Biotechnology, Inc.; and a research partnership with the Institute of Molecular and Clinical Ophthalmology Basel. Additionally, the company maintains research collaborations with both Pfizer Inc. and Apellis Pharmaceuticals, Inc., alongside a comprehensive collaboration and license agreement with Verve Therapeutics, Inc.
Biotech
Adverum Biotechnologies is a clinical-stage biotechnology research company headquartered in Redwood City, California. The company focuses on developing novel gene therapies designed to redefine ocular care and treat severe eye diseases.
Biotech
SpliceBio is a clinical-stage genetic medicines company that develops gene therapies using a proprietary Protein Splicing platform. The company focuses on treating diseases caused by mutations in large genes, with a lead clinical program targeting Stargardt disease.
Similar biotechnology company
Coave Therapeutics is a clinical-stage biotechnology company headquartered in Paris, France. The company focuses on developing life-changing gene therapies targeting rare ocular and central nervous system diseases.
Similar biotechnology company
Atsena Therapeutics, Inc. is a clinical-stage gene therapy company headquartered in Durham, North Carolina, established in 2019. The firm focuses on developing novel gene therapies to treat debilitating inherited blinding diseases using proprietary vector delivery technologies. Its scientific pipeline aims to address areas of high unmet medical need in ophthalmology.
Similar biotechnology company
SparingVision is a genomic and gene therapy medicines company translating pioneering science into vision-saving treatments, with US headquarters located in Boston, Massachusetts.
Biotech
GenSight Biologics is a clinical-stage biopharmaceutical company that develops gene therapies to treat neurodegenerative retinal diseases and central nervous system disorders. The company focuses on addressing conditions such as Leber Hereditary Optic Neuropathy (LHON), Retinitis Pigmentosa, and Geographic Atrophy using technologies like gene therapy, mitochondrial targeting sequences, and optogenetics.
Similar biotechnology company
Eyevensys is a biotechnology company developing non-viral gene therapies for ophthalmic diseases. Its platform uses electro-transfection of the eye’s ciliary muscle to enable sustained local production of therapeutic proteins for retinal and other ocular conditions.
Similar biotechnology company
Skylark Bio is a biotechnology company developing precision-targeted, locally delivered gene therapies to treat genetic hearing loss and other single-gene disorders. The company's platform aims to restore natural biological processes and hearing function, addressing conditions that affect children and individuals with genetic communication impairments.
Similar biotechnology company
Rinascera Therapeutics, Inc. is a clinical-stage biotechnology company located in Boston, Massachusetts, dedicated to transforming the treatment of rare genetic skin diseases.
Biotech
Character Biosciences is a biotechnology company that uses human genetics and functional genomics to discover and develop precision medicines. Its work has focused particularly on genetically informed therapies for age-related diseases, including ophthalmic conditions such as age-related macular degeneration.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Beacon Therapeutics and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Beacon Therapeuticsand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →